Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
At this time, many treatment options exist for primary androgen-deprivation therapy. "Standard" options with long-term results on outcome include orchiectomy, monotherapy with a luteinizing hormone-releasing hormone (LHRH) agonist, and combined androgen blockade using an LHRH agonist and antiandrogen. All treatments are associated with some morbidity related to the reduction of circulating testosterone. For this reason, "alternative" regimens are under active study to determine whether equal outcomes can be achieved with lesser toxicity.
Hellerstedt
Beth
B
University of Michigan Medical Center, Ann Arbor, Michigan 48109-0640, USA. bhellers@umich.edu
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000728:Androgens; D000813:Anilides / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004054:Diethylstilbestrol / Q000627:therapeutic use; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D018120:Finasteride / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000097:blood*; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000188:drug therapy; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D009570:Nitriles; D009919:Orchiectomy; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D016879:Salvage Therapy; D014105:Tosyl Compounds; D016896:Treatment Outcome
D000726:Androgen Antagonists; D000728:Androgens; D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D004791:Enzyme Inhibitors; D009363:Neoplasm Proteins; D009570:Nitriles; D014105:Tosyl Compounds; D007987:Gonadotropin-Releasing Hormone; D018120:Finasteride; D004054:Diethylstilbestrol; C053541:bicalutamide; D017430:Prostate-Specific Antigen